Chronic pelvic pain syndrome (MG30.00) is a persistent pain condition in which a neuropathic pain component may be a key driver of symptoms. Identifying this mechanism informs the appropriate pharmacological approach.
This protocol applies to patients with chronic pelvic pain syndrome where a neuropathic pain component is part of the clinical presentation. Addressing this mechanism specifically is central to the management strategy.
An oral neuromodulator approach is used to target the neuropathic pain component. The full protocol specifies which agents are indicated, the selection criteria between them, and the complete structured regimen.